This website uses cookies to enhance the user experience.
I

IMMUNOR AS914 405 920

Research
Limited company
Gaustadalléen 21 0349 OSLO, Norge

IMMUNOR AS

home - Immunor AS
Immunor AS is a Norwegian-based vaccine developer unlike any other. Building on comprehensively patented IP of unique elegance and power, Immunor AS is in

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Links

Organization

Chairman of the board
Years since formation
10 years
since Nov 13, 2014
Type
Limited company
VAT registered
No
Number of employees
0

Ownership

Number of shares and share classes
224,465,733
1 share class
Total number of shareholders
35
22 companies, 13 persons
Belongs to group of

Financials

Annual total result 2023
-417,741
NOK
Total equity 2023
-3,127,376
NOK
Last update: Aug 29, 2024

Management

Management / administration

NameRoleShares
Managing Director/CEO
16.04 %
indirectly

Board

NameRoleShares
Chairman
21.51 %
indirectly
Board Member
6.74 %
indirectly
ResignedBoard Member
7.55 %
indirectly

Others

NameRoleShares
H
HENKA REVISJON AS
Auditor-
Accountant-

Top 10 individual shareholders

NameRoleShares
Chairman
21.51 %
indirectly
Managing Director/CEO
16.04 %
indirectly
-
8.02 %
indirectly
Board Member
7.55 %
indirectly
Board Member
6.74 %
indirectly
-
3.42 %
indirectly
-
1.78 %
indirectly
-
1.4 %
indirectly
-
1.14 %
indirectly
Last update: May 13, 2024

Ownership

Company shareholders

NameShare classNumber of sharesShare
S
SCHJØSUS INVEST AS
Ordinary shares
54,000,000
24.06 %
K
KAG AS
Ordinary shares
48,272,720
21.51 %
Ordinary shares
25,000,000
11.14 %
W
WIVEL INVEST AS
Ordinary shares
16,936,362
7.55 %
A
A A HOLDING AS
Ordinary shares
15,136,360
6.74 %
Ordinary shares
15,000,000
6.68 %
Ordinary shares
10,500,000
4.68 %
J
JAHATT AS
Ordinary shares
6,818,028
3.04 %
J
JAKOB HATTELAND HOLDING AS
Ordinary shares
6,043,310
2.69 %
D
DIGISTEP AS
Ordinary shares
4,000,000
1.78 %
A
APEX CAPITAL AS
Ordinary shares
3,136,360
1.4 %
Ordinary shares
2,551,520
1.14 %
S
SOLON EIENDOM AS
Ordinary shares
2,045,410
0.91 %
Ordinary shares
2,000,000
0.89 %
Ordinary shares
1,729,316
0.77 %
M
MALISE AS
Ordinary shares
1,551,804
0.69 %
C
CHRISHØEG AS
Ordinary shares
1,551,804
0.69 %
G
GRAFO AS
Ordinary shares
1,363,606
0.61 %
KS
Ordinary shares
1,000,000
0.45 %
J
JAN INGE SAGEIE AS
Ordinary shares
1,000,000
0.45 %
F
FINNMIN EIENDOM AS
Ordinary shares
839,348
0.37 %
J
JARAH INVEST AS
Ordinary shares
524,524
0.23 %
T
TRE E FINANS AS
Ordinary shares
500,000
0.22 %
Ordinary shares
340,900
0.15 %
Ordinary shares
340,138
0.15 %
Ordinary shares
306,667
0.14 %
A
AROSA INVEST AS
Ordinary shares
283,934
0.13 %
Ordinary shares
280,000
0.12 %
B
BLUE HORIZON AS
Ordinary shares
268,000
0.12 %
Ordinary shares
204,540
0.09 %
Ordinary shares
200,000
0.09 %
R
RM CONSULTANTS AS
Ordinary shares
200,000
0.09 %
A
ADIANTE AS
Ordinary shares
200,000
0.09 %
Ordinary shares
198,328
0.09 %
M
MD INVESTMENTS AS
Ordinary shares
142,754
0.06 %

Shares owned by the IMMUNOR AS

NameShare classNumber of sharesShare
P
PERIOVACX AS
Ordinary shares
206,250
68.75 %
B
BIONOR HOLDING AS
NO0010813736
16,350,000
35.87 %
Last update: May 24, 2024

Group structure

  • Total operating income 2023: NOK 0
    Operating profit 2023: NOK -172,295
    Employees: 0

Financials

in NOK

Summary

Year20232021
Total operating income
0
305,043
Annual Total Result
-417,741
-223,336
Total assets
53,205
176,599
Total liabilities
3,180,581
2,000,772
Total equity
-3,127,376
-1,824,173

P&L

Year20232021
Total operating income
0
305,043
Total operating costs
172,295
567,114
Operating result
-172,295
-262,071
Financial income/costs
-245,446
38,735
Profit before tax
-417,741
-223,336
Total tax & extraordinary income/cost
0
0
Annual Total Result
-417,741
-223,336

Balance overview

Year20232021
Total fixed assets
36,216
126,600
Total current assets
16,989
49,999
Total assets
53,205
176,599
Short term debt
710,586
248,872
Long term debt
2,469,995
1,751,900
Total liabilities
3,180,581
2,000,772
Contributed capital
50,550
24,334
Retained earnings
-3,177,927
-1,848,507
Total equity
-3,127,376
-1,824,173
Total equity and liabilities
53,205
176,599

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology